PDS Biotech's Cancer Drug Hits Key Trial Goal as Q2 Losses Widen to $9.4M - Stock Titan
4 days ago • Google News
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in .
4 days ago • Google News
3 days ago • Google News
3 days ago • Google News